Michael J Allen, Amy Zhang, Prashant Bavi, Jaesung C Kim, Gun Ho Jang, Deirdre Kelly, Sheron Perera, Rob E Denroche, Faiyaz Notta, Julie M Wilson, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Sandra E Fischer, Robert C Grant, Steven Gallinger, Jennifer J Knox, Grainne M O'Kane
AIMS: The majority of pancreatic ductal adenocarcinomas (PDACs) harbour oncogenic mutations in KRAS with variants in TP53 , CDKN2A and SMAD4 also prevalent. The presence of oncogenic fusions including NTRK fusions are rare but important to identify. Here we ascertain the prevalence of NTRK fusions and document their genomic characteristics in a large series of PDAC. METHODS: Whole genome sequencing and RNAseq were performed on a series of patients with resected or locally advanced/metastatic PDAC collected between 2008 and 2020 at a single institution...
September 28, 2021: Journal of Clinical Pathology